MRK vs OPK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
OPK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.97 and low debt, these are offset by a -19.2% decline in year-over-year revenue and deeply negative profit margins. The stock is trading below its book value (P/B 0.71), but the persistent long-term price decay (-72.8% over 5 years) suggests a value trap rather than a bargain. Despite optimistic analyst price targets, the deterministic data points to a company in structural decline.
Compare Another Pair
Related Comparisons
MRK vs OPK: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and OPKO Health, Inc. (OPK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.